Mortality (Longevity):

What’s New Since January 2020? 

And What Isn’t?

Steve Goss, Chief Actuary

US Social Security Administration

2023 Living to 100 Symposium

General Session VII: Mortality Projection from a Social Security Panel

January 18, 2023
Active participation in the Society of Actuaries is an important aspect of membership. While the positive contributions of professional societies and associations are well-recognized 

and encouraged, association activities are vulnerable to close antitrust scrutiny. By their very nature, associations bring together industry competitors and other market participants. 

The United States antitrust laws aim to protect consumers by preserving the free economy and prohibiting anti-competitive business practices; they promote competition. There are both 

state and federal antitrust laws, although state antitrust laws closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities. The 

Sherman Act prohibits every contract, combination or conspiracy that places an unreasonable restraint on trade. There are, however, some activities that are illegal under all 

circumstances, such as price fixing, market allocation and collusive bidding. 

There is no safe harbor under the antitrust law for professional association activities. Therefore, association meeting participants should refrain from discussing any activity that could 

potentially be construed as having an anti-competitive effect. Discussions relating to product or service pricing, market allocations, membership restrictions, product standardization or 

other conditions on trade could arguably be perceived as a restraint on trade and may expose the SOA and its members to antitrust enforcement procedures.

While participating in all SOA in person meetings, webinars, teleconferences or side discussions, you should avoid discussing competitively sensitive information with competitors and 

follow these guidelines:

• Do not discuss prices for services or products or anything else that might affect prices

• Do not discuss what you or other entities plan to do in a particular geographic or product markets or with particular customers.

• Do not speak on behalf of the SOA or any of its committees unless specifically authorized to do so.

• Do leave a meeting where any anticompetitive pricing or market allocation discussion occurs.

• Do alert SOA staff and/or legal counsel to any concerning discussions

• Do consult with legal counsel before raising any matter or making a statement that may involve competitively sensitive information.

Adherence to these guidelines involves not only avoidance of antitrust violations, but avoidance of behavior which might be so construed. These guidelines only provide an overview of 

prohibited activities. SOA legal counsel reviews meeting agenda and materials as deemed appropriate and any discussion that departs from the formal agenda should be scrutinized 

carefully. Antitrust compliance is everyone’s responsibility; however, please seek legal counsel if you have any questions or concerns.

SOA Antitrust Compliance Guidelines

2
Presentations are intended for educational purposes only and do not 

replace independent professional judgment. Statements of fact and 

opinions expressed are those of the participants individually and, 

unless expressly stated to the contrary, are not the opinion or 

position of the Society of Actuaries, its cosponsors or its 

committees. The Society of Actuaries does not endorse or approve, 

and assumes no responsibility for, the content, accuracy or 

completeness of the information presented. Attendees should note 

that the sessions are audio-recorded and may be published in 

various media, including print, audio and video formats without 

further notice.

Presentation Disclaimer

3
4

Perspective: “Aging” Not Mainly from Mortality

Aging (change in age distribution) mainly due to drop in birth rates

4
What’s New? COVID-19; Pandemics

 COVID-19 swept across the globe and continues 

– Enhanced population mobility

– Highly evolving virus

 Remarkable new MRNA vaccine; recent bivalent booster

– But only about 16% of eligible in US have taken it

 New variants are arriving regularly; mitigations have waned

 Now endemic?

 Will post-COVID conditions constrain longevity in the future?

5
In the US, BQ Overtook BA in November; 

XBB Now Matches BQ, and Dominates in NY/NJ

6
Across Europe and the Americas—

The Fall/Winter Wave Rising in December

7

Reported Cases Rising Reported Deaths Increasing in the New Year
Rise in Hospitalizations in January Makes Clear 

that New Cases are Increasingly Underreported 

8
Cases and Deaths are Lower for Those Vaccinated, 

But How Much Due to Care and Greater Mitigation?

9
Relative Changes in Death Rates by Age, Total and PIC, Varied 

by Strain; Did Delta Reflect Earlier Vaccination for 65+?

10
Note the Lag in Reporting of Deaths in the US;

Estimated Excess Deaths Rising in Late November 

11
But Excess Deaths Are Not All From COVID;

Currently May Be Largely From Other-Than-PIC 

12
For Latest Complete Provisional Quarter, 

Age-Sex-Adjusted Death Rates Are All Elevated Over 2019

13

NCHS Provisional Age-Adjusted Death Rates 2019Q3 2021Q3

Ratio 

2021Q3/2019Q3

Alzheimer disease 27.6 29.7 1.08

COVID-19 #N/A 115.6 #N/A

Cancer 145.4 148.5 1.02

Chronic liver disease and cirrhosis 11.1 14.6 1.32

Chronic lower respiratory diseases 33.6 34.6 1.03

Diabetes 19.8 24.8 1.25

Drug overdose 22.4 33.5 1.50

Falls, ages 65 and over 64.2 75.7 1.18

Firearm-related injury 12.4 15.5 1.25

Heart disease 150.5 169.7 1.13

HIV disease 1.3 1.3 1.00

Homicide 6.4 8.7 1.36

Hypertension 8.2 10.3 1.26

Influenza and pneumonia 8.9 10.1 1.13

Kidney disease 11.7 13.1 1.12

Parkinson disease 8.3 9.6 1.16

Pneumonitis due to solids and liquids 4.1 4.9 1.20

Septicemia 8.7 10.2 1.17

Stroke 34.8 39.8 1.14

Suicide 14.7 14.7 1.00

Unintentional injuries 51.3 67.6 1.32

Total 645.4 852.5 1.32

Total w/o COVID 645.4 736.9 1.14
Now, Considerations in Projecting Mortality

 Frequency of future pandemics?

 Variation by age and over time periods 

 Variation by earnings level

 Changing causes of death

 Cohort considerations

 Health spending, obesity, smoking, opioids

 Is there a limit on human longevity?

 Our projections for the United States

14
Pandemics in the Future

 Over the last 100 years, mortality has been about cause 

reduction

 But if pandemics raise deaths 15% for 2 years in every 20 years

– Then the level of mortality would be raised by 1.5% per year on average

 But how about residual compromising effects—post-COVID?

– How much will viability be diminished for the survivors? 

 Earlier death later in life might be the larger factor

– As with other compromising factors like smoking

15
Variation by Age Has Been Substantial

Reduction in mortality at higher ages is inherently more difficult

16
Mortality Decline Has Varied Over Time

Conditions: Antibiotics/economy 1936-54; Medicare/Medicaid 1968-82

17
Mortality Experience: All Ages

Reductions falling short of expectations since 2009

18

700

750

800

850

900

950

1,000

1,050

1,100

1990 1995 2000 2005 2010 2015 2020 2025

Age-Sex-Adjusted Death Rates (per 100,000)

Total, All Ages

2014TR

2017TR

2020TR

2021TR

2022TR

Actual
Mortality Experience: Ages 65 and Over

Reductions falling short of expectations since 2009

19

4,000

4,200

4,400

4,600

4,800

5,000

5,200

5,400

5,600

5,800

6,000

1990 1995 2000 2005 2010 2015 2020 2025

Age-Sex-Adjusted Death Rates (per 100,000)

Ages 65 and Older

2014TR

2017TR

2020TR

2021TR

2022TR

Actual
Mortality Experience: Under Age 65

Experience far worse than expectations since 2009

20

200

250

300

350

400

1990 1995 2000 2005 2010 2015 2020 2025

Age-Sex-Adjusted Death Rates (per 100,000)

Ages Under 65

2014TR

2017TR

2020TR

2021TR

2022TR

Actual
Mortality By Career-Average Earnings Level: 

Actuarial Study #124

Age group 65-69 relative mortality ratios—not diverging?

21
Mortality Decline by Cause of Death: 

Annual rate of change from 1979 to 2019

22
Age-Adjusted Death Rates for Heart Disease, Cancer, Stroke, 

and Unintentional Injuries: United States, 1900-2021

(courtesy Robert Anderson, NCHS)

Notes: Data are from the National Vital Statistics System. Prior to 1933, data are for death-registration States only. Data for 2021 are provisional.

23

Heart disease

Cancer

Unintentional injury Stroke
Age-Adjusted Death Rates for Heart Disease, Cancer, Stroke, 

and Unintentional Injuries: United States, 2000-2021

(courtesy Robert Anderson, NCHS)

0

50

100

150

200

250

300

Age-adjusted death rate (per 100,000 population)

Heart disease

Cancer

Stroke Unintentional injury

Chronic liver disease

Notes: Data are from the National Vital Statistics System. Prior to 1933, data are for death-registration States only. Data for 2021 are provisional.

COVID-19

21
Age-Adjusted Death Rates for Selected Causes: 

United States, 2000-2021

(courtesy Robert Anderson, NCHS)

0

5

10

15

20

25

30

35

Age-adjusted death rate (per 100,000 population)

Drug overdose

Suicide

Alcohol induced

Notes: Data are from the National Vital Statistics System. Data for 2021 are provisional.

22
Developing Assumptions by Cause

 Scientific approach reflecting biology and epidemiology

 Trustees and SSA/OCACT develop in consultation with other 

experts

 CDC/NIH

 Johns Hopkins survey of medical researchers and clinicians

26
Cohort Considerations

 Post-World War 2 births—special conditions:

– Antibiotics when young; statins, etc. later

 What does change up to age x say above age x?

– If cohort is fundamentally healthier at x: 

Then expect lower mortality over age x

– But if medical interventions have just reduced deaths:

Then cohort mortality over age x could be worse, with increased numbers of 

impaired survivors

– What does one cohort imply for the next cohort?

Further changes depend on conditions, not trend

27
How Future Conditions Might Change

 Smoking decline for women

– Started and stopped later than men

 Obesity—sedentary lifestyle

 Health spending—must decelerate

– Advances help only if they apply to all

 Human limits

– Increasing understanding of deceleration

28
Trends in Obesity: US 1971-2006

Sam Preston 2010—must consider cumulative effects; increasing duration of obesity for aged in future

29
Health Spending Cannot Continue to Rise at Historical Rates

Note Trustees’ deceleration

30
Is There an Omega?

It appears we are rectangularizing the survival curve; few actually live to 100

31
32

Death Rates Will Continue to Decline: 

But How Fast and for Whom?

 Must understand past and future conditions

– Persistent historical “age gradient”

– Avoid simple extrapolation of past periods

» Cannot ignore changing conditions

 “Limits” on longevity due to physiology

 Latter half of 20th century was extraordinary

» So deceleration seems likely

» Cause-specific rates allow basis for assumptions

– Results: in the 1982 TR, we projected LE65 for 2013 to be 19.0; 

actual was 19.1
Ultimate (2046 to 2096) Projected Rates of Decline: 

Similar to Period Since 1900 for Age 50+

33

1900 to 

2019

2009 to 

2019

Projected 

2046 to 

2096

Under Age 15 2.97 1.46 1.52

Ages 15 - 49 1.43 -0.55 0.85

Ages 50 - 64 0.99 0.03 0.96

Ages 65 - 74 0.91 0.92 0.71

Ages 85 + 0.58 0.24 0.55

Total 1.02 0.43 0.72
Projected US Age-Sex-Adjusted Death Rates, All Ages 

(Note importance of log scale)

34
Projected Age-Sex-Adjusted Death Rates, Ages 65 and Over 

(Note importance of log scale)

35
Ultimately, the Changing Age Distribution of the 

Population is the Main Factor for Social Security

36
For More Information...

http://www.ssa.gov/oact/

 Documentation of Trustees Report data & assumptions 

https://www.ssa.gov/oact/TR/2022/2022_LongRange_Demographic_Assumptions.pdf

 2022 SOA ImpACT Conference, panel 13A with leading demographers 

https://www.ssa.gov/oact/presentations/scgoss_20221027.pdf

 Historical and projected mortality rates

https://www.ssa.gov/oact/HistEst/DeathHome.html

 Annual Trustees Reports 

https://www.ssa.gov/oact/TR/index.html

37
38

Fill Out the 

Evaluation and 

Claim Your 

CPD Credits